PDCD1 and metastatic neoplasm: The majority of patients enrolled (63 (72.4%)) had metastatic disease; most (85 (97.7%)) had received prior therapy with a median of 3 (range 1–9) therapies, and 24 patients (27.6%) had received prior immunotherapy (all except for one patient had immunotherapy that included PD-1/PD-L1 inhibition).